BIOMAT Database Logo BIOMAT Database Logo

Thalidomide for severe acute graft-versus-host disease. 1988

O Ringdén, and J Aschan, and L Westerberg

UI MeSH Term Description Entries
D008297 Male Males
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

O Ringdén, and J Aschan, and L Westerberg
Thalidomide for graft-versus-host disease.
April 1988, Lancet (London, England),
O Ringdén, and J Aschan, and L Westerberg
Thalidomide for graft-versus-host disease.
November 1988, Lancet (London, England),
O Ringdén, and J Aschan, and L Westerberg
Thalidomide treatment for chronic graft-versus-host disease.
May 1991, British journal of haematology,
O Ringdén, and J Aschan, and L Westerberg
Thalidomide for treatment of graft-versus-host disease.
September 1988, Bone marrow transplantation,
O Ringdén, and J Aschan, and L Westerberg
Thalidomide for chronic graft-versus-host disease in children.
December 1988, Lancet (London, England),
O Ringdén, and J Aschan, and L Westerberg
Thalidomide as salvage therapy for chronic graft-versus-host disease.
November 1995, Blood,
O Ringdén, and J Aschan, and L Westerberg
Thalidomide for graft-versus-host disease after bone marrow transplantation.
February 1988, Lancet (London, England),
O Ringdén, and J Aschan, and L Westerberg
Thalidomide for the treatment of chronic graft-versus-host disease.
April 1992, The New England journal of medicine,
O Ringdén, and J Aschan, and L Westerberg
Life-threatening acute pancreatitis due to thalidomide therapy for chronic graft-versus-host disease.
May 2008, Annals of hematology,
O Ringdén, and J Aschan, and L Westerberg
Severe intestinal involvement in acute graft versus host disease.
April 2022, Gastroenterologia y hepatologia,
Copied contents to your clipboard!